['rheumatoid arthritis']
['methotrexate', 'folic acid']

        Inclusion Criteria:

          -  Signed informed consent

          -  Active rheumatoid arthritis according to criteria of American College of
             Rheumatologists (2010), that was diagnosed at least 6 months prior to screening.

          -  Active rheumatoid arthritis at screening despite of therapy with methotrexate for 3
             last months.

          -  Use of methotrexate in stable dose for at least 4 weeks before screening (10-25 mg per
             week).

          -  History of ineffective treatment with basic antiinflammatory drugs (including
             methotrexate).

        Exclusion Criteria:

          -  Previous therapy of rheumatoid arthritis with monoclonal antibodies (including
             anti-tumor necrosis factor drugs)

          -  Felty's syndrome

          -  Functional status - class IV according to ACR classification (1991)

          -  Low activity of rheumatoid arthritis (DAS28-CRP(4) index less than 3.2)

          -  Patient needs corticosteroids in a dose more than 10 mg (recalculated to prednisolone)
             before signing informed consent.

          -  Patients needs equal of less than 10 mg prednisolone but the dose was not stable for
             last 4 weeks prior to infliximab treatment

          -  Prior use of disease-modifying antirheumatic drugs including methotrexate,
             sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before
             randomization.

          -  Prior use of alkylating agents for up to 12 months prior to signing informed consent.

          -  Intraarticular use of corticosteroids for up to 4 weeks before randomization.

          -  Prior use of live or attenuated vaccines for up to 8 weeks before signing informed
             consent.

          -  Diagnosis of tuberculosis.

          -  Body mass more than 130 kg.
      